May 7, 2025 | Press Releases
Complete Pathologic Response reported in 2 patients in the Third Cohort with cutaneous squamous cell carcinoma, complementing results in prior cohort Phio to present trial results to date at a podium presentation at Society for Investigative Dermatology (SID) Annual...
May 1, 2025 | Press Releases
Registration Link for Presentation and live Q&A to take place, Wednesday, May 7, 2025 at 2:00 pm ESTMarlborough, Massachusetts–(May 1, 2025) – Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing...
Apr 9, 2025 | Press Releases
-Phio’s lead clinical siRNA compound PH-762 demonstrates supportive safety profile in third cohort, permitting escalation in next dose concentrationMarlborough, Massachusetts–(April 9, 2025) – Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a...
Apr 3, 2025 | Press Releases
To be presented at 11th Annual Immunotherapy of Cancer (ITOC) Conference in Munich, Germany Marlborough, Massachusetts–(Newsfile Corp. – April 3, 2025) – Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biotechnology company...
Mar 31, 2025 | Press Releases
Continues advancing clinical trial for INSTASYL siRNA lead product candidate PH-7623rd Cohort now fully enrolled in on-going clinical studyMarlborough, Massachusetts–(Newsfile Corp. – March 31, 2025) – Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a...
Mar 10, 2025 | Press Releases
Interim Results from clinical study for cutaneous carcinomas presented at Late-Breaking Research SessionMarlborough, Massachusetts–(Newsfile Corp. – March 10, 2025) – Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage biotechnology company...
